Affiliations: [a] Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin, China | [b] Department of Pediatric Surgery, First Hospital of Jilin University, Changchun, Jilin, China | [c] Department of Gynecology and Obstetrics, First Hospital of Jilin University, Changchun, Jilin, China
Correspondence:
[*]
Corresponding author: Dayun Sui, Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University, No.1163 Xinmin Street, Changchun 130021, Jilin, China. Tel.: +86 431 8561 9252; E-mail: suidy@jlu.edu.cn.
Abstract: BACKGROUND AND OBJECTIVE: N6-methyladenosine (m6a) is the most abundant form of methylated modification in eukaryotic mRNA. However, the role of m6A-related genes in neuroblastoma (NB), one of the most common paediatric malignant tumours, is not well known. This study aimed to determine the prognostic role of m6A-related genes in neuroblastoma. METHODS: We analysed the expression of 20 published m6A methylation regulators in 498 patients with NB from the Gene Expression Omnibus database. To determine the independent prognostic factors, we used univariate Cox analysis, the least absolute shrinkage and selection operator (LASSO) regression. The multivariate Cox analysis was used to construct a prognostic risk prediction model. 120 NB tissues from “Therapeutically Applicable Research To Generate Effective Treatments” (TARGET ) database was used to test the prognostic value. Gene set enrichment analysis was performed to discover the potential biological function of the m6A signature. RESULTS: The risk prediction model consisted of five genes (METT14, WTAP, HNRNPC, YTHDF1 and IGF2BP2). The receiving operating characteristic curve showed the high exactitude of the risk model. Cox regression analysis revealed that the risk model was an independent prognostic factor of overall survival. These results were reproduced using another published independent dataset. Further functional enrichment analysis suggested the involvement of the 5-gene signature in several malignancies. CONCLUSION: The five m6A regulatory genes identified in this study enable clinical prognosis of NB and may serve as novel therapeutic targets for NB.
